

Index

A

- N*-Acetyltransferase (NAT), *Legionella*, 65–66
- ActA, *Listeria monocytogenes* invasion role, 128
- Actin, toxin targeting, 265, 269
- Agr proteins
 - autoinducer protein therapeutic targeting, 206
 - quorum sensing, 203–206
- AI-2, quorum sensing, 213–214, 216
- AmgR, 190–191
- Antisense RNA. *See* Small noncoding RNA
- AphA, 186–187, 214–215
- Apoptosis, CagA inhibition, 93
- ARAP2, 123
- AspH1, 293
- ASPP2
 - CagA interactions, 92–95
 - p53 interactions, 92–93
- Autophagy
 - Francisella* activation, 82
 - Shigella*, 170

B

- Bacillus anthracis*
 - edema toxin, 271–272
 - lethal toxin, 272
- Bacillus cereus*, quorum sensing, 206–208
- Bacillus subtilis*
 - biofilms, 244–245
 - quorum sensing, 206
- Bacteriophage. *See* Phage therapy
- BAHD1, 291, 293, 295
- BamA, contact-dependent growth inhibition, 233–234
- Barriers. *See* Blood–brain barrier; Host specificity; Intestinal barrier; Placental barrier
- Bartonella*
 - Brucella* relationship, 1–4
 - diseases, 3–4
 - host cell invasion functions
 - adhesion molecules, 7, 9
 - VirB, 4–7
 - virulence factors, 5
 - immune evasion
 - flagellin mutation, 12
 - lipopolysaccharide modification, 11–12
 - T cell-independent responses, 12

- infection sequel, 2–4
- prospects for study, 12–13
- uptake studies
 - Bartonella/Brucella*-containing vacuoles, 9–10
 - erythrocytes, 10
 - in vivo studies, 10–11
- BBB. *See* Blood–brain barrier
- BdcA, biofilm targeting, 252
- β -adrenergic receptor, signaling in *Neisseria meningitidis* adhesion, 142–144
- BFP. *See* Bundle-forming pili
- Biofilm
 - adhesion targeting
 - antimatrix agents, 251
 - enzymes, 251
 - mannosides, pilicides, and curlicides, 249–250
 - metal chelators, 251–252
 - polysaccharides, 250
 - signal transduction interference, 250–251
 - antibiotic tolerance, 247
 - bactericides
 - antimicrobial peptides, 248–249
 - phage therapy, 247–248
 - silver nanoparticles, 248
 - dispersal manipulation for disassembly, 252
 - extracellular biofilms
 - dispersal, 244–245
 - formation, 240–243
 - maturation, 243–244
 - intracellular biofilms, 245–247
 - overview, 239–240
 - prospects for study, 252–253
- Blood–brain barrier (BBB)
 - brain microvascular endothelial cell adhesion and transcytosis of microbes, 310–311
 - composition, 309
 - inflammation and permeability, 312–313
 - Neisseria meningitidis* crossing, 144, 311
 - overview, 308–309
 - paracellular invasion, 311–312
 - pathogen invasion pathways, 309–310
 - phagocyte-facilitated invasion, 312
- BMAP-27, biofilm targeting, 249
- BMAP-28, biofilm targeting, 249
- Botulinum toxin, 271
- Brain microvascular endothelial cell. *See* Blood–brain barrier

Index

Brucella

- Bartonella* relationship, 1–4
 - diseases, 3–4
 - host cell invasion functions
 - adhesion molecules, 7, 9
 - VirB, 4–7
 - virulence factors, 5
 - immune evasion
 - flagellin mutation, 12
 - lipopolysaccharide modification, 11–12
 - T cell-independent responses, 12
 - infection sequel, 2–4
 - placental barrier crossing by *Brucella abortus*, 307
 - prospects for study, 12–13
 - uptake studies
 - Bartonella/Brucella*-containing vacuoles, 9–10
 - erythrocytes, 10
 - in vivo studies, 10–11
- Btp1, 11
- Bundle-forming pili (BFP), enteropathogenic
Escherichia coli, 48
- Burkholderia*, contact-dependent growth inhibition,
235–236

C

- CagA. *See Helicobacter pylori*
- cag* pathogenicity island. *See Helicobacter pylori*
- CAI-1, quorum sensing, 213–214, 216
- cAMP. *See Cyclic AMP*
- CAR. *See Cocksackie and adenovirus receptor*
- Cat scratch disease. *See Bartonella*
- Cbp proteins, pneumococcus, 153–155, 157
- CbpA, 311
- CDI. *See Contact-dependent growth inhibition*
- CdiA, contact-dependent growth inhibition, 228–236
- CdiI, contact-dependent growth inhibition, 228, 231,
234–235
- CdrA, biofilm maintenance, 243
- CdtA, 271
- CdtB, 271
- CdtC, 271
- CFH. *See Complement factor H*
- CHBP, 270
- ChePEP, *Helicobacter pylori*, 100
- Chlamydia trochomatis*
- cell exit, 26
 - cell invasion
 - inclusions, 24
 - mechanism in epithelial cells, 22–24
 - membrane trafficking regulator interactions,
24–25
 - organelle interactions for nutrient acquisition,
25–26
 - peri-Golgi transport, 24
 - development cycle, 21–22

- diseases, 21
 - epigenetic effects, 291–293
 - genetic manipulation, 32–33
 - genome, 32
 - host viability maintenance, 30–32
 - immune response
 - chemokines and cytokines, 28–30
 - detection, 26–28
 - evasion, 28–30
 - innate immunity, 28
 - prospects for study, 33
- Chromatin. *See Epigenetics*
- CIITA, 288
- Clathrin-mediated endocytosis, *Listeria monocytogenes*
invasion, 121–122
- Clostridial toxins, 269, 271, 303
- Clostridium difficile*, intestinal barrier disruption, 303
- CNF1 toxin, 270, 272
- Cocksackie and adenovirus receptor (CAR), 304
- Cocksackievirus B, placental barrier crossing, 307
- Competence-stimulating peptide (CSP), 153
- Complement factor H (CFH), 326, 350
- Contact-dependent growth inhibition (CDI)
- Burkholderia*, 235–236
 - CDI pathway
 - CdiA-CT toxin activities, 234–235
 - model, 232
 - target cell binding, 232–234
 - modularity of systems, 228–231
 - orphan toxin-immunity gene pairs, 231–232
 - overview, 227–228
 - prospects for study, 237
 - Rhi system homology, 236
- Cortactin, 143
- Coxiella burnettii*, placental barrier crossing, 306
- CqsA, quorum sensing, 213
- CqsS, quorum sensing, 214, 216
- Crk, 172
- CSP. *See Competence-stimulating peptide*
- CsrA, biofilm dispersal, 244
- Curlicides, biofilm targeting, 249–250
- CviI, quorum sensing, 208
- CviR, quorum sensing, 208
- Cyclic AMP (cAMP), toxin targeting of signaling,
271–272
- CysK, contact-dependent growth inhibition, 235

D

- Dab2, 122
- DapZ, 189–190
- DHODH*, 346
- Dispersin B, biofilm targeting, 251
- DNA methylation. *See Epigenetics*
- DNase I, biofilm targeting, 251
- Dot/Icm secretion system, *Legionella*, 62–64

E

- E-cadherin, InlA interactions, 120, 123, 127
- EcN. *See Escherichia coli* Nissle 1917
- Edema toxin, 271–272
- EDTA, biofilm targeting, 251–252
- Endoplasmic reticulum (ER), toxin targeting of stress responses, 271
- Endothelial cell. *See Neisseria meningitidis*
- Enterococcus faecalis*, biofilms, 243, 250–251
- Enterocyte, microbe translocation, 303–304
- Enterohemorrhagic *Escherichia coli*
 - infection models, 46–51
 - overview, 41–43
 - prospects for study, 51–52
 - secretion system, 42
- Enteropathogenic *Escherichia coli*
 - infection models
 - comparison of models, 49–51
 - in vitro, 43–45
 - in vivo, 45–49
 - overview, 41–43
 - prospects for study, 51–52
 - secretion system, 42–43
- Epigenetics
 - Ankyrin-repeat bacterial proteins, 291
 - ATP-dependent remodeling of nucleosomes, 278, 282
 - bacteria signaling to chromatin
 - DNA methylation, 289–290
 - histone modification, 285, 288–289
 - noncoding RNA and RNA splicing, 290–291
 - overview, 285–287
 - bacterial enzymes in histone modification, 291
 - bacterial proteins in chromatin remodeling, 291–293
 - DNA methylation, 278, 280–281, 283
 - histone modification, 278, 280–284
 - memory
 - Helicobacter pylori*-induced cancer, 288–290, 294
 - overview, 285
 - severe inflammation and lipopolysaccharide tolerance, 293–294
 - overview of bacteria effects, 277–278
 - prospects for study, 294–295
 - regulation by noncoding RNA and RNA splicing factors, 284–285
- ER. *See* Endoplasmic reticulum
- ErbB2, 143
- Escherichia coli*. *See* Enterohemorrhagic *Escherichia coli*; Enteropathogenic *Escherichia coli*; *Shigella*; Uropathogenic *Escherichia coli*
- Escherichia coli* Nissle 1917 (EcN), 380–384
- EspB, enteropathogenic *Escherichia coli*, 48
- N-Ethyl maleimide (NEM), biofilm targeting with analogs, 251

F

- Factor H-binding protein (fHbp)
 - levels and susceptibility to disease, 366
 - Neisseria* invasion role, 138
 - reverse vaccinology
 - binding studies, 365–366
 - identification as vaccine antigen, 363–364
 - meningococcal epidemiology and typing, 365
 - pathogenesis role, 364–365
 - structural vaccinology, 365
- FasX, 184
- fHbp. *See* Factor H-binding protein
- FimH, 246, 248
- Flagellin, *Bartonella* and *Brucella* mutation for immune evasion, 12
- Francisella*
 - cell entry, 74–75
 - innate immune response
 - detection, 81
 - inflammasome activation, 81
 - xenophagic capture, 82
 - life cycle, 74–75
 - overview, 73–74
 - phagosomes
 - bactericidal function interference, 76–78
 - escape by *Francisella*, 78–79
 - maturation, 75–76
 - prospects for study, 82–83
 - replication in cytosol, 79–80
- FsrA, 250
- FsrC, 250
- FyuA, 395

G

- GlmU, biofilm targeting, 251
- GtcA, 128

H

- HapR, 186–187
- HapR, quorum sensing, 214, 216
- HBB, 350
- HBV. *See* Hepatitis B virus
- HCV. *See* Hepatitis C virus
- Helicobacter pylori*
 - CagA
 - apoptosis inhibition, 93
 - ASPP2 interaction and effects, 92–95
 - host cell effects
 - adhesion loss, 91
 - matrix invasion, 91–92
 - polarity loss, 91
 - host-cell interactions, 89
 - knockout studies, 101
 - tyrosine phosphorylation, 88–89

Index

- Helicobacter pylori* (Continued)
 cag pathogenicity island genes, 88
 epigenetics in cancer, 288–290, 294
 intestinal barrier disruption, 303
 overview, 87–88, 99–100
 persistent infection
 chemotaxis role, 100
 diseases, 99–100
 epithelial microenvironment, 100–102
 immune evasion, 102–103
 transmission studies, 103
 prospects for study, 95
 type IV secretion system
 core complex, 90
 energetics, 90–91
 overview, 90
- Heme oxygenase 1 (HO-1), 379
- Hemin-binding proteins, *Bartonella* and *Brucella*, 9
- Hemolytic uremic syndrome. *See* Enterohemorrhagic *Escherichia coli*
- Hepatitis B virus (HBV), human genome diversity and infection, 348–349
- Hepatitis C virus (HCV), human genome diversity and infection, 348
- Hepatocyte growth factor receptor, InlB interactions, 120–121
- Hfq, RNA binding, 182, 189, 194
- Hip1R, 122
- Histone. *See* Epigenetics
- HIV. *See* Human immunodeficiency virus
- HO-1. *See* Heme oxygenase 1
- Host barriers. *See* Blood–brain barrier; Host specificity; Intestinal barrier; Placental barrier
- Host specificity
 evolutionary perspective, 321–322
 gene-for-gene versus multifactorial models, 322
 generalists versus specialists, 321–322
 genomic signatures of specificity
 decay, 327–328
 lateral gene transfer, 329–330
 rearrangements, 328–329
 importance of study, 333
 molecular mechanisms
 adherence, 324–325
 iron acquisition and complement resistance, 325–326
 replication, 325
 toxins, 325
- Salmonella enterica* serovars, 322–323
- techniques for study
 cell culture, 330
 comparative zoology, 330–331
 humanized mice, 331–333
 transmission implications
 Salmonella serovars
 generalists, 326
 specialists, 326–327
 Yersinia species, 327
- virulence implications
 host as driver of pathogen variation, 324
 specialization effects, 324
 Yersinia species, 323–324
 zoonosis, 333
- Human genome diversity
 complex susceptibility to infection
 bacteria, 349–350
 parasites, 350
 viruses, 348–349
 data sets, 342–343
 deleterious mutation burden, 344
 disease influence, 344–346
 evolutionary approach to infectious disease, 350–351
 Mendelian defects in immunity and infection, 346–347
 natural selection influences, 343–344
 Neisseria meningitidis, single nucleotide polymorphisms, and susceptibility to disease, 366
 population history, 343
- Human immunodeficiency virus (HIV), *Escherichia coli* Nissle 1917 studies, 380
- I**
- IL-10. *See* Interleukin-10
- Inflammasome, *Francisella* activation, 81
- Inflammation
 blood–brain barrier permeability effects, 312–313
 epigenetic memory, 293–294
 meningitis damage, 158–159
 Shigella response, 170–171
- Inflammatory bowel disease (IBD), probiotic therapy, 378
- InlA, *Listeria monocytogenes* invasion role, 118–120, 124–127, 304
- InlB, *Listeria monocytogenes* invasion role, 118–121, 124–126, 304, 308
- InlE, *Listeria monocytogenes* invasion role, 126
- Interleukin-10 (IL-10), probiotic production, 378
- Intestinal barrier
 enterocyte translocation, 303–304
 host cell sensing of lumen content and microbe exploitation, 304–305
 paracellular invasion, 305–306
 probiotics. *See* Probiotics
 structure, 302–303
 tight junction disruption by enteropathogens, 303
- Intimin, enteropathogenic *Escherichia coli*, 48
- IpaB, 172
- IpaC, 172
- IpaD, 172
- IpaH9.8, 293
- IpgaA, 173

IpgB1, 173
IpgB2, 173–174
IpgD, 171, 173
IQGAP1, 106
Iron, acquisition in host specificity, 325–326
IspC, 128

K

Klebsiella pneumoniae, biofilms, 246–247

L

Lactic acid bacteria. *See* Probiotics
Laminin receptor, 311
Laminin receptor, bacteria invasion role, 158
LasI, quorum sensing, 208, 213
LasR, quorum sensing, 208–213
LcrV, 378–379
Legionella
 genomic diversity, 58–60
 host-mimicking proteins
 coevolution with eukaryotic cells, 65–68
 virulence factors, 61–64
 mobilome
 accessory genes, 68–70
 overview of mobile genetic elements, 60–61
 versatility, 69–70
 overview, 57–58
 epigenetic effects, 288
Leprosy, human genome diversity and infection, 350
Lethal toxin, 272
Lgt, 128
Lhd1, 293
Lipopolysaccharide (LPS)
 Bartonella and *Brucella* modification, 11–12
 epigenetic memory in tolerance, 293–294
Listeria monocytogenes
 enterocyte translocation, 303–304
 host specificity, 325
 invasion of cells
 ActA role, 128
 cell lines for study, 125
 clathrin-mediated endocytosis, 121–122
 cytoskeleton and membrane rearrangements,
 122–124
 InlA role, 118–120, 124–126
 InlB role, 118–121, 124–126
 InlF role, 126
 LLO role, 126–127
 prospects for study, 128–129
 signaling cascades, 119
 life cycle, 118
 overview, 117–118
 placental barrier crossing, 307–308
Listeriolysin O (LLO)

epigenetic effects, 288
Listeria monocytogenes invasion role, 126–127
phagosome disruption, 263–264

LLO. *See* Listeriolysin O

LpeA, 128
LPS. *See* Lipopolysaccharide
LubX, *Legionella*, 62
LuxI, quorum sensing, 208
LuxO, 186, 213
LuxP, quorum sensing, 213–214
LuxQ, quorum sensing, 213–214
LuxR, quorum sensing, 208
LysM, 154
Lysozyme, bacteria contamination treatment in plant
 cultures, 396

M

Malta fever. *See* *Brucella*
Meningitis. *See* *Streptococcus pneumoniae*
Meningococcus. *See* *Neisseria meningitidis*
Messenger RNA (mRNA)
 cis-regulatory regions and sensing, 180–181
 small noncoding RNA derivation from untranslated
 regions, 188–190
Met, activation by InlB, 121–122
MgtC, 181
Microtubule-organizing center (MTOC), *Chlamydia*
 transport, 24
MisL, *Salmonella* persistence role, 107
mRNA. *See* Messenger RNA
MTAN, quorum sensing, 214, 216
MTOC. *See* Microtubule-organizing center
MucR, biofilm maintenance, 243
Mycobacterium, human genome diversity and
 infection, 350
MYH3, 346

N

NADPH oxidase, phagosome production and
 Francisella interference, 76–78
NanA, 154
NAT. *See* *N*-Acetyltransferase
Neisseria gonorrhoeae, host specificity, 324–325
Neisseria meningitidis. *See also* Factor H-binding protein
 host specificity, 325–326
 overview, 135–136
 pathogenesis
 blood phase, 137–139
 endothelial cell interactions
 blood–brain barrier crossing, 144, 311
 overview, 136–137, 139–140
 pilus-mediated interaction, 142–144
 purpura fulminans, 144–145
 signaling consequences, 143–144

Index

- Neisseria meningitidis*. See also Factor H-binding protein (*Continued*)
- pilus
 - β -adrenergic receptor signaling in adhesion, 142–144
 - biogenesis, 140–141
 - host cell interaction mechanisms, 141–142
 - single nucleotide polymorphisms and susceptibility to disease, 366
 - vaccination, 363–366
- NEM. See *N*-Ethyl maleimide
- Noncoding RNA. See Small noncoding RNA
- Norspermidine, biofilm dispersal, 252
- Nucleosome. See Epigenetics
- NuRD, 282–283
- O**
- Opa, 324
- OspE, 293
- P**
- p53
- ASPP2 interactions and CagA, 92–93
 - proteosomal degradation, 93, 95
- p300/CBP, 283
- PAFr. See Platelet-activating factor receptor
- PapR, quorum sensing, 207–208
- PawA, 154
- PBC-1, biofilm targeting, 249
- PcIA, 155
- PDGF. See Platelet-derived growth factor receptor
- PeI, biofilm maintenance, 243
- Phage therapy
- animal models, 393
 - biofilm targeting, 247–248
 - clinical studies, 393–394
 - curative agents, 395
 - historical perspective, 391–392
 - immunity and resistance, 395–396
 - limitations, 393
 - prophylaxis, 394–395
 - prospects, 401
 - tail-associated lytic enzymes as antibacterial agents, 396
 - vaccine delivery
 - advantages, 399–401
 - DNA vaccine, 398–399
 - overview, 396–397
 - phage display, 397–398
- PhoPQ, *Salmonella* persistence role, 107
- Phosphoinositides
- Listeria monocytogenes* invasion role, 122
 - Shigella* invasion role, 174
 - Phosphorylcholine, *Streptococcus pneumoniae* invasion role, 155
- PhrS, 186, 188
- Pilins, *Neisseria meningitidis*, 140–141
- Placental barrier, microbe translocation, 306–308
- Platelet-activating factor receptor (PAFr)
- blood–brain barrier, 311
 - Streptococcus pneumoniae* invasion role, 155, 158
- Platelet-derived growth factor receptor (PDGF), *Chlamydia* binding role, 23
- PlcR, quorum sensing, 207–208
- Pneumococcus. See *Streptococcus pneumoniae*
- Porins, small noncoding RNA regulation, 184
- PqsH, quorum sensing, 211
- PqsR, 188, 210
- Probiotics
- Escherichia coli* Nissle 1917, 380–384
 - gut microbiota function, 376–377
 - lactic acid bacteria and intestinal barrier reconstitution, 378–380
 - overview, 375–376
 - prospects for study, 384–385
 - types and uses, 377–378
- PrpA, 12
- Pseudomonas aeruginosa*
- biofilms, 242–244, 249–250, 252
 - quorum sensing, 209–213
- Pseudomonas aeruginosa*, small noncoding RNA regulation, 186, 192
- Psl, biofilm maintenance, 243
- PsrP, 155
- PtbA, 155
- PTP-7, biofilm targeting, 249
- Purpura fulminans. See *Neisseria meningitidis*
- Q**
- Qrr, quorum sensing, 213–214, 216
- QS. See Quorum sensing
- QscR, quorum sensing, 210, 212–213
- QseB, 250
- QseC, 250
- Quorum sensing (QS)
- circuits, 202–203
 - Gram-negative bacteria
 - LuxI/LuxR system, 208
 - Pseudomonas aeruginosa*, 209–213
 - Vibrio cholerae*, 213–216
 - Gram-positive bacteria
 - Bacillus cereus*, 206–208
 - components, 203
 - peptide-binding transcription factor roles, 206
 - Staphylococcus aureus*, 203–206
 - overview, 201–203
 - prospects for study, 216–217
 - small noncoding RNA gradients, 185–187

R

- Rab, *Chlamydia* interactions, 24–25
- Rac1, *Chlamydia* binding role, 23
- Reactive oxygen species (ROS), phagosome production and *Francisella* interference, 76–78
- Regulatory T cell (Treg), *Salmonella* persistence role, 106–107
- RhlI, quorum sensing, 211, 213
- RhlR, quorum sensing, 209–211, 213
- Rho, toxin targeting, 265, 269
- Rhs, contact-dependent growth inhibition, 229–230, 236
- Rip kinase, 273
- RNA. *See* Messenger RNA; Small noncoding RNA
- ROS. *See* Reactive oxygen species
- Rotavirus, intestinal barrier disruption, 303
- RsmY, 192
- RsmZ, 192
- Rubella virus, placental barrier crossing, 307

S

- Salmonella*
 - host specificity
 - comparative zoology, 330–331
 - genomic signatures, 327–329
 - humanized mouse studies, 331–333
 - replication, 325
 - Salmonella enterica* serovars, 322–323
 - transmission implications
 - generalists, 326
 - specialists, 326–327
 - intestinal barrier crossing, 304–305
 - life cycle, 109
 - mRNA *cis*-regulatory regions and sensing, 181
 - overview, 102–103
 - persistent infection
 - bacterial proteins in intestinal persistence, 107
 - gut microbiota interactions in colonization, 110
 - host cell migration control, 106
 - innate immunity evasion, 104
 - mouse studies, 104–105
 - pathogenicity islands, 105–106
 - regulatory T cell role, 106–107
 - transmission studies, 107–110
- SdhA, *Legionella*, 62
- Septins, *Listeria monocytogenes* invasion role, 123–123
- SgrS, 188, 195
- ShdA, *Salmonella* persistence role, 107
- Shigella*
 - autophagy, 170
 - cytoskeletal reorganization regulation
 - IpgaA, 173
 - IpgB1, 173
 - IpgB2, 173–174
 - IpgD, 173
 - epithelial integrity maintenance, 170–171
 - Escherichia coli* phylogeny, 165–166
 - inflammatory response, 170–171
 - invasion
 - calcium signaling, 174
 - filopodial capture, 168–169
 - IpaB role, 172
 - IpaC role, 172
 - prospects for study, 174
 - type III secretion system role, 166, 168–169, 171–172
 - tyrosine kinase signaling, 172–173
 - overview, 165
 - phagocytic vacuole lysis, 169–170
 - toxins, 270
 - virulence gene regulation by environment, 166–168
- Signature-tagged mutagenesis (STM), *Streptococcus pneumoniae*, 153–154
- Silver nanoparticles, biofilm targeting, 248
- Single nucleotide polymorphism. *See* Human genome diversity
- Small noncoding RNA (sRNA) *Pseudomonas aeruginosa*
 - quorum sensing, 212
 - antisense RNA functions, 190–192
 - binding proteins, 182–184
 - classification, 182
 - dual-function RNAs, 187–188
 - epigenetic regulation, 285, 290–291
 - prospects for study, 192–195
 - quorum sensing, 185–187
 - trans*-acting RNAs
 - derivation from messenger RNA untranslated regions, 188–190
 - protein regulation, 192
 - regulatory mechanisms, 184, 186
 - virulence gene regulation, 187
- SMAP-29, biofilm targeting, 249
- SNAREs, toxin targeting, 271
- Sortases, pneumonococcus pilus, 152–153
- Species specificity. *See* Host specificity
- SPI1, 105–106
- SPI2, 105–106
- Spl, *Legionella*, 65–66
- SprA1, 190–192
- SreA, 188–189
- SretH, 154
- sRNA. *See* Small noncoding RNA
- Staphylococcus*, biofilms, 251–252
- Staphylococcus aureus*, quorum sensing, 203–206
- STAT1, 347
- STIM, 347
- STM. *See* Signature-tagged mutagenesis
- Streptococcus agalactiae*, intestinal barrier crossing, 305–306

Index

- Streptococcus pneumoniae*
bacteremia, 157
blood–brain barrier crossing, 311
capsule, 152, 157
colonization mediation, 154
epidemiology, 150–152
genome, 153–154
invasion strategies in pneumonia, 154–157
meningitis
 invasion strategies, 157–158
 model of inflammatory damage, 158–159
overview, 149–150
pili, 152–153
prospects for study, 159–160
surface composition and proteins, 152–153
transformation, 153
vaccination, 360
Subtilase toxin, 272
- T**
- TARP, *Chlamydia* binding role, 23
TbpB, 326
T cell. *See* Regulatory T cell
Tc toxin, 269
TcpA, 187
TcpH, quorum sensing, 215
TcpP, quorum sensing, 215
TeNT, 271
TFF. *See* Trefoil factor family
Tight junction
 blood–brain barrier, 312
 disruption by enteropathogens, 303
TLRs. *See* Toll-like receptors
TOCA-1, 170
Toll-like receptors (TLRs)
 Chlamydia detection, 26–27
 Escherichia coli Nissle 1917 interactions, 381–382
 Francisella detection, 81
 Helicobacter pylori evasion, 102
 Salmonella evasion, 104
 Streptococcus pneumoniae detection, 155–156, 158
Toxins. *See also specific toxins*
 classification, 263–265
 host specificity role, 325
 infection roles, 272–273
 prospects for study, 273
 targets
 actin, 265, 269
 cAMP signaling, 271–272
 cytosolic factors, 266–268
 DNA, 271
 endoplasmic reticulum stress responses, 271
 Rho, 265, 269
 SNAREs, 271
 translational machinery, 270–271
 ubiquitylation system, 269–270
Toxoplasma gondii, placental barrier crossing, 306–307
Translation, toxin targeting of machinery, 270–271
Transmission
 Helicobacter pylori, 103
 host specificity implications
 Salmonella serovars
 generalists, 326
 specialists, 326–327
 Yersinia species, 327
 Salmonella, 107–110
Trefoil factor family (TFF), 380
Treg. *See* Regulatory T cell
Trw, *Bartonella* and *Brucella* adhesion, 7
TSIX, 284
Tuberculosis, human genome diversity and infection, 350
Tularemia. *See* *Francisella*
- U**
- Ubiquitylation, toxin targeting of system, 269–270
UPEC. *See* Uropathogenic *Escherichia coli*
Uropathogenic *Escherichia coli* (UPEC)
 epigenetic effects, 290
 biofilms, 240, 242–247, 249
- V**
- Vaccines
 pathogenesis studies in vaccine development, 358–360
 phage delivery
 advantages, 399–401
 DNA vaccine, 398–399
 overview, 396–397
 phage display, 397–398
 prospects
 high-throughput sequencing, 368
 structural vaccinology, 366–367
 systems vaccinology, 367–368
 reverse vaccinology for pathogenesis studies
 factor H–binding protein
 binding studies, 365–366
 identification as vaccine antigen, 363–364
 meningococcal epidemiology and typing, 365
 pathogenesis role, 364–365
 structural vaccinology, 365
 overview, 360–363
VASP, 123
Vep proteins, *Bartonella* virulence role, 6
Vibrio cholerae
 quorum sensing, 213–216
 small noncoding RNA regulation, 187
Vir proteins, *Shigella*, 166, 171

VirB, *Bartonella* and *Brucella* virulence role, 4–7
VrrA, 187
VspR, 187

X

XIAP, 347
XIST, 284

Y

YbeY, 183–184

Yersinia enterocolitica, host specificity, 323

Yersinia pestis, host specificity, 323–324, 327,
329–330

Yersinia pseudotuberculosis

host specificity, 323–324, 327, 329–330

mRNA *cis*-regulatory regions and sensing, 181

YopM, 293

Z

ZirTS, *Salmonella* persistence role, 107